[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 201,237,536
  • Shares Outstanding, K 4,465,000
  • Annual Sales, $ 46,792 M
  • Annual Income, $ 15,509 M
  • EBIT $ 23,190 M
  • EBITDA $ 26,518 M
  • 60-Month Beta 0.77
  • Price/Sales 4.22
  • Price/Cash Flow 9.45
  • Price/Book 6.22

Options Overview Details

View History
  • Implied Volatility 38.58% (+0.73%)
  • Historical Volatility 34.57%
  • IV Percentile 10%
  • IV Rank 10.79%
  • IV High 64.20% on 10/09/25
  • IV Low 35.49% on 12/31/25
  • Expected Move (DTE 8) 1.47 (3.31%)
  • Put/Call Vol Ratio 0.61
  • Today's Volume 36,861
  • Volume Avg (30-Day) 74,514
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 1,400,503
  • Open Int (30-Day) 1,489,194
  • Expected Range 42.92 to 45.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.83
  • Number of Estimates 5
  • High Estimate $0.87
  • Low Estimate $0.78
  • Prior Year $0.97
  • Growth Rate Est. (year over year) -14.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.02 +16.75%
on 04/23/26
47.79 -7.11%
on 05/11/26
+4.97 (+12.61%)
since 04/21/26
3-Month
35.12 +26.40%
on 03/30/26
47.79 -7.11%
on 05/11/26
-3.03 (-6.39%)
since 02/20/26
52-Week
35.12 +26.40%
on 03/30/26
81.44 -45.49%
on 06/13/25
-23.81 (-34.91%)
since 05/21/25

Most Recent Stories

More News
Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets

EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:MMA),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END

MMA : 0.4900 (-3.73%)
BPC.CN : 0.4550 (+2.25%)
PNGAF : 0.3225 (-1.68%)
NVO : 44.39 (-1.51%)
HIMS : 24.01 (+4.21%)
LLY : 1,041.65 (+2.24%)
Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The market for peptide-based health and performance products has been growing fast as more consumers focus on fitness,...

MMA : 0.4900 (-3.73%)
BPC.CN : 0.4550 (+2.25%)
PNGAF : 0.3225 (-1.68%)
NVO : 44.39 (-1.51%)
HIMS : 24.01 (+4.21%)
LLY : 1,041.65 (+2.24%)
From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook

Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of demand.

NVO : 44.39 (-1.51%)
LLY : 1,041.65 (+2.24%)
Supreme Court Rejects Drugmakers’ Challenge to Medicare Price Negotiation Program

The U.S. Supreme Court on Monday declined to hear a pharmaceutical industry challenge to the Medicare drug price negotiation program created under the Inflation Reduction Act, leaving in place lower court...

NVO : 44.39 (-1.51%)
JNJ : 231.73 (+1.05%)
BMY : 59.55 (+1.73%)
2 Ways to Play the Big Pharma Patent Cliff

With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.

NVO : 44.39 (-1.51%)
IBB : 169.06 (+0.68%)
ARGX : 816.22 (+1.49%)
PFE : 25.95 (+0.62%)
XBI : 132.78 (+0.81%)
This Hot Weight-Loss Drug Stock May Be a Surprise Challenger

The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player closely.

VKTX : 30.68 (+4.21%)
NVO : 44.39 (-1.51%)
LLY : 1,041.65 (+2.24%)
Hims & Hers Bets Big on GLP-1 Drugs, But Investors Want Profits Now

Hims & Hers delivered a sharp earnings miss as GLP-1 and international expansion costs surged. Investors now face a classic tradeoff between near-term margins and long-term growth.

HIMS : 24.01 (+4.21%)
NVO : 44.39 (-1.51%)
Novo Nordisk A/S Q1 Earnings Call Highlights

Novo Nordisk A/S (NYSE:NVO) said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy pill in the U.S., continued expansion of its obesity franchise and a series of pipeline...

NVO : 44.39 (-1.51%)
Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?

Hims & Hers Health posted a Q1 FY2026 double miss, with an EPS loss of $0.40 and revenue of $608.1 million, sending shares down more than 12% after hours.

HIMS : 24.01 (+4.21%)
NVO : 44.39 (-1.51%)
Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates

EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:PFE),(NYSE:NVO),(NYSE:HIMS),(NYSE:LLY) EQNX::TICKER_END

BPC.CN : 0.4550 (+2.25%)
PNGAF : 0.3225 (-1.68%)
NVO : 44.39 (-1.51%)
HIMS : 24.01 (+4.21%)
LLY : 1,041.65 (+2.24%)
PFE : 25.95 (+0.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 45.59
2nd Resistance Point 45.09
1st Resistance Point 44.74
Last Price 44.39
1st Support Level 43.89
2nd Support Level 43.39
3rd Support Level 43.04

See More

52-Week High 81.44
Fibonacci 61.8% 63.75
Fibonacci 50% 58.28
Fibonacci 38.2% 52.81
Last Price 44.39
52-Week Low 35.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.